TITLE

FDA grants approval of new dosage form for fentanyl

PUB. DATE
August 2009
SOURCE
Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p12
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article announces the approval given by the U.S. Food and Drug Administration (FDA) to Onsolis, a medication that delivers opioid fentanyl through the mucous membranes of the mouth via an absorbable film that sticks to the inside of the cheek.
ACCESSION #
43476036

 

Related Articles

  • New Fentanyl Approvals Hint At Track for Class-Wide REMS. Serebrov, Mari // BioWorld Insight;7/11/2011, Vol. 19 Issue 28, p3 

    The article reports on the essence of risk evaluation and mitigation strategies (REMS) on the Federal Drug Administration (FDA) approval of fentanyl products. It discusses the competition between Onsolis and the fast-acting fentanyl products for cancer pain discovery wherein the REMS for Onsolis...

  • Archimedes Breakthrough Pain Drug Gets Pain-Free REMS. Moran, Nuala // BioWorld International;7/6/2011, Vol. 16 Issue 27, p1 

    The article reports on the effort of Archimedes Pharma Ltd. to create its U.S. operations, winning an approval from the U.S. Food and Drug Administration (FDA) for Lazanda, the nasally delivered formulation of the anesthetic fentanyl, in the treatment of cancer pain. The formulation is...

  • Archimedes Breakthrough Pain Drug Gets Pain-Free REMS. Serebrov, Mari; Moran, Nuala // BioWorld Today;7/6/2011, Vol. 22 Issue 129, p1 

    The article reports on the approval received by Archimedes Pharma Ltd. from the U.S. Food and Drug Administration (FDA) for its fentanyl drug Lazanda. It notes that Lazanda's pain-free risk evaluation and mitigation strategy (REMS) and intranasal delivery could give it a competitive advantage...

  • BDSI's Cancer Pain Patch on Pathway to Approval. Young, Donna // BioWorld Today;8/29/2008, Vol. 19 Issue 169, p1 

    The article highlights the increase in the share price of BioDelivery Sciences International Inc. on the news that Onsolis, the firm's BEMA fentanyl pain patch, is close to approval. The review of the cancer pain patch has been completed by the U.S. Food and Drug Administration (FDA) according...

  • BDSI's Cancer Pain Patch on Pathway to Approval.  // Bioworld Week;9/1/2008, Vol. 16 Issue 35, p4 

    The article reports on the near approval of BioDelivery Sciences International Inc.'s BEMA fentanyl pain patch for cancer, which resulted to its soaring stock prices. Recently, the U.S. Food and Drug Administration (FDA) finished the review of Onsolis without any problems found of the...

  • New tablet manages breakthrough pain. LoBuono, Charlotte // Drug Topics;11/20/2006, Vol. 150 Issue 22, pHSE4 

    The article reports on the Food & Drug Administration's approval of fentanyl buccal tablets, Fentora from Cephalon, for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioids for their persistent cancer pain. Fentora has a bioavailability...

  • Generic Version of Pain Patch.  // FDA Consumer;May/Jun2005, Vol. 39 Issue 3, p3 

    Reports on the approval granted by the U.S. Food and Drug Administration to Mylan Technologies Inc. for its generic version of the Duragesic Patch manufactured by Alza Corp. Information on the pain management patch; Information on fentanyl, the main component of the patch.

  • Apotex to Sell Hisamitsu Fentanyl Patch.  // Chain Drug Review;10/26/2009, Vol. 31 Issue 18, p68 

    The article reports that Apotex Corp. has signed an exclusive distribution with Hisamitsu Pharmaceutical Co. Inc. to sell the Fentanyl Transdermal System in the U.S. The Food and Drug Administration (FDA) approved the Fentanyl Transdermal System for the management of chronic pain. Jeff Watson,...

  • News Briefs.  // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1499 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved a new formulation of docetaxel and a needleless intravenous (i.v.) connector with chlorhexidine and silver and zero-fluid displacement.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics